The Claim
In obese mice, withdrawal of incretin-based therapeutics results in weight regain, and prior treatment with bimagrumab prevents preferential accrual of fat mass while promoting regain of lean mass during this rebound weight gain.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, stopping incretin-based drugs causes weight to return, but previous treatment with bimagrumab ensures that the regained weight consists more of muscle than fat.
See the scientific wording
In obese mice, withdrawal of incretin-based therapeutics leads to weight regain, but prior treatment with bimagrumab prevents preferential fat mass accrual and promotes lean mass regain during rebound weight gain.
When a person stops taking weight-loss drugs, the body usually regains fat. But if they previously took a drug that blocks ACVR2A/B receptors, their body burns more calories as heat instead of storing fat, so they regain muscle instead of fat.
What the research says
1 studyStudy: 2180-LB: Bimagrumab Augments Metabolic Rate to Improve Incretin-Induced Weight Loss in Obese Mice
When obese mice stopped taking weight-loss drugs, they usually regained fat — but if they had taken bimagrumab before, they regained muscle instead. The study found exactly that.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.